<DOC>
	<DOCNO>NCT00500292</DOCNO>
	<brief_summary>The purpose study determine whether treatment ZACTIMA ( vandetanib ) combination FOLFOX effective FOLFOX alone colorectal cancer patient fail therapy irinotecan fluoropyrimidine contain regimen .</brief_summary>
	<brief_title>A Phase II Study 2 Doses ZD6474 ( Vandetanib ) Combination With FOLFOX v FOLFOX Alone Treatment Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Progression follow treatment metastatic colorectal cancer Have fail therapy irinotecan fluoropyrimidine contain regimen Have World Health Organisation ( WHO ) performance status 02 life expectancy &gt; 12 week Previous treatment small molecule tyrosine kinase inhibitor VEGFR EGFR Prior monoclonal antibody permit , ( eg , cetuximab , bevacizumab ) Previous adjuvant therapy irinotecan within 12 month randomisation More one prior course chemotherapy treatment metastatic colorectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>zactima</keyword>
</DOC>